This activity is expired and is no longer available for CME credit.


Oral Therapies in MS Management: Where We Are and What Is on the Horizon

Author(s)/Faculty: Amit Bar-Or, MD, FRCPC; Bruce Cree, MD, PhD, MAS
Release Date: 11/30/2015Expiration Date: 11/29/2016
Credit Type: CMENumber of Credits: 0
Content Type: LectureProvider:
Multiple sclerosis (MS) is a chronic, progressive disease associated with inflammation, demyelination, and axonal damage or destruction in the brain and spinal cord. Approximately 400,000 individuals in the United States and >2.5 million worldwide are affected by MS. Debilitating symptoms and a worsening of disease activity over time place a considerable burden on patients, diminishing quality of life. Disease-modifying therapies (DMTs) can reduce the frequency and severity of clinical attacks, slow the progression of disability, and reduce accumulation of lesions within the brain and spinal cord. Parenteral DMTs are effective in the management of relapsing-remitting disease. However, these agents are subject to several limitations, including safety concerns and the need for administration via injection. Newer oral drugs have been introduced to improve the safety and tolerability of MS treatment, provide greater convenience, and promote adherence. The oral medications fingolimod, teriflunomide, and dimethyl fumarate are presently available, and additional agents, including ozanimod and laquinimod, are under investigation. Data from clinical trials have suggested that progress in the development of novel oral DMTs may provide patients with safer treatment options. This CME activity will review the efficacy and safety of current oral DMTs, as well as emerging oral drugs that may be poised to enter the therapeutic armamentarium.